MYRIAD GENETICS, INC.

(MYGN)
  Report
Real-time Estimate Cboe BZX  -  05/27 02:57:13 pm EDT
22.80 USD   +7.80%
05/26Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022
GL
05/26Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022
AQ
05/26Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/23/2022 05/24/2022 05/25/2022 05/26/2022 05/27/2022 Date
21.7(c) 21.35(c) 21.26(c) 21.15(c) 22.68 Last
319 399 377 518 324 651 292 538 198 933 Volume
-1.23% -1.61% -0.42% -0.52% +7.23% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 689 M - -
Net income 2022 -61,7 M - -
Net cash position 2022 327 M - -
P/E ratio 2022 -34,7x
Yield 2022 -
Sales 2023 737 M - -
Net income 2023 -35,6 M - -
Net cash position 2023 404 M - -
P/E ratio 2023 -67,1x
Yield 2023 -
Capitalization 1 699 M 1 699 M -
EV / Sales 2022 1,99x
EV / Sales 2023 1,76x
Nbr of Employees 2 400
Free-Float 97,9%
More Financials
Company
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company primarily provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing the disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease... 
More about the company
Ratings of Myriad Genetics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about MYRIAD GENETICS, INC.
05/26Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portf..
GL
05/26Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portf..
AQ
05/26Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portf..
CI
05/16Immunovia strengthens its US team through the appointment of Natalie Carfora as Head of..
AQ
05/11TRANSCRIPT : Myriad Genetics, Inc. Presents at Bank of America 2022 Healthcare Conference,..
CI
05/06MYRIAD GENETICS INC Management's Discussion and Analysis of Financial Condition and Re..
AQ
05/05TRANSCRIPT : Myriad Genetics, Inc., Q1 2022 Earnings Call, May 05, 2022
CI
05/05Myriad Genetics Q1 Adjusted Loss Narrows, Revenue Declines; Reiterates 2022 Guidance
MT
05/05Earnings Flash (MYGN) MYRIAD GENETICS Reports Q1 EPS $-0.03, vs. Street Est of $-0.09
MT
05/05Earnings Flash (MYGN) MYRIAD GENETICS Reports Q1 Revenue $164.9M, vs. Street Est of $15..
MT
05/05Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022
GL
05/05Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022
AQ
05/05Myriad Genetics, Inc. Provides Earnings Guidance for the Fiscal Year 2022
CI
05/05Myriad Genetics, Inc. Reports Goodwill and Long-Lived Asset Impairment Charges for the ..
CI
05/05MYRIAD : Q1 Earnings Snapshot
AQ
More news
News in other languages on MYRIAD GENETICS, INC.
05/26Myriad Genetics présente ses avancées en matière de médecine de précision avec l'expans..
05/05Myriad Genetics réduit sa perte ajustée au 1er trimestre et diminue ses revenus ; réitè..
05/05Earnings Flash (MYGN) MYRIAD GENETICS annonce un chiffre d'affaires de 164,9 millions d..
05/05Myriad Genetics, Inc. fournit des prévisions de bénéfices pour l'année fiscale 2022
05/05Myriad Genetics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2..
More news
Analyst Recommendations on MYRIAD GENETICS, INC.
More recommendations
Chart MYRIAD GENETICS, INC.
Duration : Period :
Myriad Genetics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MYRIAD GENETICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Last Close Price 21,15 $
Average target price 23,36 $
Spread / Average Target 10,4%
EPS Revisions
Managers and Directors
Paul J. Diaz President, Chief Executive Officer & Director
R. Bryan Riggsbee Chief Financial Officer, Treasurer & Executive VP
S. Louise Phanstiel Chairman
Kevin R. Haas Chief Technology Officer
Thomas P. Slavin Chief Medical Officer